ArticleRheumatology international2024
Prevalence of comorbidities and cardiovascular risk factor management in hand osteoarthritis: a cross-sectional study.
Article in Rheumatology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of comorbidities in patients with erosive hand osteoarthritis (EHOA), a monocentric study.Frontiers in aging · 2026Article
- Central obesity and radiographic severity are associated with symptomatic hand osteoarthritis: a population-based cross-sectional study.Rheumatology international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the prevalence of comorbidities and management of cardiovascular risk factors according to established guidelines for patients with hand osteoarthritis.
methodsA cross-sectional study was conducted that included 110 hand osteoarthritis patients. The clinical parameters (pain, function, grip strength, quality of life, sarcopenia, and comorbidities) were assessed along with cardiovascular (CV) risk factors (blood pressure, body mass index, and dyslipidaemia). CV risk was assessed using SCORE2 or SCORE2-OP algorithms. Comparisons of patient characteristics were performed using Student's or chi-squared tests.
resultsTwenty-eight patients were identified with comorbidities, and they tended to be older, male, and with a lower quality of life. The median SCORE2 was 5.1%. SCORE2 was negatively associated with grip strength (r=-0.27, p = 0.02). There was no difference in SCORE2 between hand osteoarthritis patients with (n = 60) and without (n = 50) neuropathic-like pain (5.6 ± 3.7 versus 6.2 ± 3.3%; p = 0.38). Among the 40 patients with an intermediate or high CV risk, 33 (82.5%) were off target for low-density lipoproteins (LDL) level with no lipid-lowering treatment (n = 29) or an insufficient statin treatment (n = 4). Obesity was observed in 24 patients (21.8%) and 30 (27.3%) were overweight. Forty-two patients (41.2%) had blood hypertension (41 systolic and one diastolic patient) despite treatment for 9 patients.
conclusionsWe found an increased CV risk in hand osteoarthritis patients who had an insufficient LDL cholesterol target achievement. Hand osteoarthritis patients appear to have a pro-atherogenic profile. These results suggest that CV risk factors should be assessed in patients with hand osteoarthritis and managed according to recommended guidelines.
Indexed as
Identifiers
39708140What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.